Immunocore, a closely held U.K. biotech company, said it has raised $320 million in venture funding, in the latest sign of investor appetite for treatments that harness the immune system to fight cancer
from WSJ.com: US Business http://ift.tt/1LlcaeF
via IFTTT
No comments:
Post a Comment